Open now · EURATOM Innovation Actions · HORIZON-EURATOM-2026-01-05
Expected Outcome:
the project results are expected to contribute to the following outcomes:
Scope:
radiological and nuclear technologies are integral to modern healthcare. They play a crucial role in cancer care – from early detection and diagnosis to treatment and palliative support. They also support the diagnosis and management of a wide range of other conditions (including cardiovascular and neurological diseases). Each year, patients throughout the EU benefit from the application of nuclear medicine in the diagnosis and treatment of cancer and other serious conditions.
Innovations such as targeted radionuclide therapy (also known as radioligand therapy) are reshaping medicine by enabling more precise and personalised treatment. Medical radioisotopes are essential both for diagnostics and for an expanding array of therapeutic applications (particularly in oncology).
Trimmed here, the full scope, expected outcomes and award criteria are on the official topic page ↗.
| Item | Estimate | Note |
|---|---|---|
| Drafting effort | 6–8 weeks | single submission |
| Partner search | 4–8 weeks | runs in parallel, and it is the part that slips |
| Your own money | €857K | 30% of project cost, over the project's life |
| Time to first payment | 6–9 months | cut-off → evaluation → grant agreement |
These are Bemzu's estimates from the call's structure (the number of stages and whether a consortium is required) not figures published by the Commission. Only the co-financing share is read from the call itself.
Two kinds of row. Most are the sentence we read the condition from, quoted out of the call itself. Some say plainly that they are not a quotation but the programme's own rule for this type of action, the EU portal publishes a table of contents where the conditions should be, so for a Research and Innovation Action the rate comes from the rulebook rather than from the fiche.
| Condition | Quoted from the call, or the rule behind it |
|---|---|
| Consortium size | Not quoted from this call — Innovation Actions under the Horizon Europe rules are at least three independent legal entities from three different Member States or Associated Countries, at least one established in a Member State. |
| Funding rate | Not quoted from this call — Innovation Actions under the Horizon Europe rules are funded at 70% of eligible costs for profit-making organisations, and 100% for non-profit legal entities — the rate shown here is the one that applies to a company. |
| Maturity | Activities are expected to focus on technology readiness levels 5 to 7 (indicative but not mandatory, depending on the innovative potential of the field). |
Eight questions, no account, nothing sent anywhere. You will know which of the 1526 open calls you can actually enter before you finish your coffee.
Check my fit
